Abstract
Introduction: TA90 is a tumor-associated 90-kD glycoprotein antigen expressed on most melanoma cells, including those of CancerVax, a polyvalent allogeneic whole-cell vaccine. Previous studies have shown that a TA90 antigen-antibody immune complex (IC) in the serum of patients with melanoma is a marker of subclinical tumor burden and a strong prognostic factor. We hypothesized that the induction of TA90-IC during postoperative adjuvant CancerVax therapy might indicate vaccine-mediated immune destruction of subclinical melanoma cells with release of TA90, and thereby serve as a surrogate marker of vaccine efficacy.
Methods: From 1993 to 1997, 219 melanoma patients were enrolled in a prospective phase II trial of CancerVax plus bacille Calmette-Guerin (BCG) after complete tumor resection. Coded serum samples were prospectively collected and analyzed for TA90-IC before and 2, 4, 8, 12, and 16 weeks after initiation of CancerVax therapy. TA90-IC seroconverters were those patients whose negative TA90-IC values (< .410) became positive (≥ .410) after initiation of CancerVax treatment.
Results: Before CancerVax therapy, 51 patients had positive TA90-IC values and 168 patients had negative TA90-IC values. During CancerVax treatment, all 51 positive patients remained positive, 79 (47%) negative patients seroconverted to positive, and 89 (53%) negative patients remained negative. Seroconverters had higher 2-year rates of disease-free survival (59% vs. 32%; P < .006) and overall survival (78% vs. 63%; P < .02) than did patients whose TA90-IC values remained positive.
Conclusions: CancerVax induces TA90-IC in melanoma patients with subclinical disease. TA90-IC seroconverted patients have significantly improved disease-free and overall survival compared with TA90-IC positive patients. TA90-IC is an important prognostic factor that can serve as a surrogate marker for the clinical efficacy of CancerVax.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
Barth A, Morton DL. The role of adjuvant therapy in melanoma management. Cancer 1995; 75: 726–34.
Haigh PI, DiFronzo LA, Gammon G, Morton DL. Vaccine therapy for patients with melanoma. Oncology 1999; 13: 1561–82.
Morton DL, Foshag LJ, Hoon DSB, et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 1992; 216: 463–82.
Morton DL, Barth A. Vaccine therapy for malignant melanoma. CA Cancer J Clin 1996; 46: 225–44.
Shen P, Foshag L, Essner R, et al. Postoperative adjuvant therapy using a polyvalent melanoma vaccine improves overall survival of patients with primary melanoma. Proc Am Soc Clin Oncol 1999; 18: 533a.
Jones RC, Kelley M, Gupta RK, et al. Immune response to polyvalent melanoma cell vaccine in AJCC stage III melanoma: an immunologic survival model. Ann Surg Oncol 1996; 3: 437–45.
Hsueh EC, Gupta RK, QiK, Morton DL. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 1998; 16: 2913–20.
Euhus DM, Gupta RK, Morton DL. Induction of antibodies to a tumor-associated antigen by immunization with a whole melanoma cell vaccine. Cancer Immunol Immunother 1989; 29: 247–54.
Gupta RK, Morton DL. Monoclonal antibody-based ELISA to detect glycoprotein tumor-associated-antigen-specific immune complexes in cancer patients. J Clin Lab Anal 1992; 6: 329–36.
Hsueh EC, Gupta RK, QiK, Yee R, Leopoldo ZC, Morton DL. TA90 immune complex predicts survival following surgery and adjuvant vaccine immunotherapy for stage IV melanoma. Cancer J Sci Am 1997; 3: 364–70.
Kelley MC, Jones RC, Gupta RK, Yee R, Stern S, Wanek L, Morton DL. Tumor-associated antigen TA-90 immune complex assay predicts subclinical metastasis and survival for patients with early stage melanoma. Cancer 1998; 83: 1355–61.
Barth A, Hoon DSB, Foshag LJ, et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 1994; 54: 3342–5.
Sirott MN, Bajorin DF, Wong GYC. Prognostic factors in patients with metastatic melanoma. Cancer 1993; 72: 3091–8.
Tartour E, Blay JY, Dorval T. Predictors of clinical response to interleukin-2-based immunotherapy in melanoma patients: a French multi-institutional study. J Clin Oncol 1996; 14: 1697–1703.
Viac J, Schmitt D, Claudy A. Circulating vascular endothelial growth factor (VEGF) is not a prognostic indicator in malignant melanoma. Cancer Lett 1998; 125: 35–8.
Author information
Authors and Affiliations
Corresponding author
Additional information
Presented at the Society of Surgical Oncology Annual Meeting, New Orleans, Louisiana, March 16-19, 2010434_2001_Article_198.
Rights and permissions
About this article
Cite this article
Tsioulias, G.J., Gupta, R.K., Tisman, G. et al. Serum TA90 Antigen-Antibody Complex as a Surrogate Marker for the Efficacy of a Polyvalent Allogeneic Whole-Cell Vaccine (CancerVax) in Melanoma. Ann Surg Oncol 8, 198–203 (2001). https://doi.org/10.1007/s10434-001-0198-y
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s10434-001-0198-y